All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Miltenyi Biomedicine, Nurix Therapeutics, Roche, and Thermo Fisher Scientific and supported through independent educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
Astrid PavlovskyThe virtual Lymphoma Hub Satellite Symposium, at the European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, saw a panel of international experts come together to discuss how to manage patients with relapsed and/or refractory (R/R) lymphoma. Professor Astrid Pavlovsky, Fundaleu, Buenos Aires, AR, discussed how she would treat a patient with chronic lymphocytic leukemia (CLL) who has relapsed after treatment with venetoclax + rituximab.
Satellite Symposium | Patient with R/R CLL— Latin American perspective
Professor Astrid Pavlovsky begins with an overview of the prevalence of common B-cell non-Hodgkin lymphoma types in Central and South America. She then highlights the lack of targeted therapies and diagnostic techniques in some Latin American countries.
Astrid Pavlovsky recommends therapeutic intervention with a Bruton’s tyrosine kinase (BTK) inhibitor, and presented data from the ELEVATE CLL R/R study, which compared ibrutinib versus acalabrutinib for the treatment of high-risk CLL.
Satellite Symposium | Patient with R/R CLL— Latin American perspective
If you would like to download the slides from Astrid Pavlovsky's presentation, click below.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is the primary reason you use bridging therapy in patients with DLBCL awaiting CAR T-cell therapy?